Andrew Kung

Andrew Kung is a prominent figure in the field of pediatric hematology and oncology, currently serving as the Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center since July 2016. In addition to this role, Andrew is a co-founder and board member of Isabl and serves on the Scientific Advisory Boards of several companies, including Karyopharm Therapeutics Inc., Emendo Biotherapeutics, and DarwinHealth. Andrew's prior academic appointments include Chief of the Division of Pediatric Hematology/Oncology at Columbia University Irving Medical Center and Associate Professor at Dana-Farber Cancer Institute. Educational qualifications include a PhD in Cancer Biology and an MD from Stanford University School of Medicine, complemented by a Bachelor's degree in Biochemistry from Florida State University.